Artículos del autor

solaci

Day 3

ATOMIC: Omecamtiv Mecarbil does not relieve dyspnea in patients with heart failure

This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on...
solaci -
Day 3

Group Tour of France: good news for cyclists.

The benefits of regular physical activity are well established, but there are some controversies related to the...
solaci -
Day 3

Resynchronization therapy is not beneficial in patients with heart failure and narrow QRS

Resynchronization therapy has shown benefits reducing morbidity and mortality in patients with heart failure and wide QRS....
solaci -
Day 3

AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis

This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and...
solaci -
Day 3

BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.

The acute chest pain is responsible for more than 11 % of queries to an emergency service...
solaci -
Day 2

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes....
solaci -
Day 2

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4...
solaci -
Day 2

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces...
solaci -